Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MG-K10 humanized monoclonal antibody in adults with moderate-to-severe asthma (Ib/II)
CTR20221013Phase 2Completed
- Sponsor
- Medigene AG
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of comekibart in asthma, sponsored by Medigene AG. Started Apr 2022; status: completed.
02
Drugs
comekibart
03
Conditions
asthma
Beyond the preview
Go deeper on CTR20221013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221013.